阿西美辛治疗强直性脊柱炎的药物经济学评价  

Pharmacoeconomic Evaluation of Acemetacin in the Treatment of Ankylo-sing Spondylitis

作　　者：杨珍珍 曹培 任赛赛 张志清[1] YANG Zhen-zhen;CAO Pei;REN Sai-sai;ZHANG Zhi-qing(The Second Hospital of Hebei Medical University,Shijiazhuan 050000,China)

机构地区：[1]河北医科大学第二医院,河北石家庄050000

出　　处：《海峡药学》2021年第12期114-117,共4页Strait Pharmaceutical Journal

摘　　要：目的评价阿西美辛缓释胶囊治疗强直性脊柱炎的临床疗效及成本效用。方法回顾性分析663名强直性脊柱炎患者,按照治疗方式分为A组和B组,A组服用阿西美辛缓释胶囊进行治疗,B组服用双氯芬酸钠肠溶片。治疗12个月后分析比较两组患者的临床疗效,并采用成本效用方法进行药物经济学评价。结果 A组和B组质量调整生命年分别为0.792和0.770年,医保报销费用分别为1219和859元,ICUR为16364元。分别以治疗疗效加减标准差和药品价格上下浮动20%作敏感分析,评价结果对疗效和药品价格稳定。结论在治疗需每日服用非甾体抗炎药治疗的强直性脊柱炎患者,阿西美辛缓释胶囊相比双氯芬酸钠肠溶片具有成本效用。OBJECTIVE To evaluate the clinical efficacy and cost-utility of acemetacin sustained-release capsules in the treatment of ankylosing spondylitis.METHODS 663 patients,from a Three-A hospital of Beijing,with ankylosing spondylitis were selected as objects.Patients were divided into group A(treated with acemetacin)and group B(treated with diclofenac sodium).Cost-utility analysis was used for phannacoeconomic evaluation.RESULTS The quality adjusted life years of group A and group B were 0.792 and 0.770 years,with cost 1219 and 859 yuan respectively,and ICUR was 16,364 yuan.With therapeutic effect and 20% more or less in drug price as a sensitivity analysis,the evaluation results were stable for the efficacy and the drug price.CONCLUSION Compared with diclofenac sodium enteric-coated tablets,acemetacin sustained-release capsules is more cost-utility in the treatment of patients with ankylosing spondylitis who require daily non-steroidal anti-inflammatory drugs.

关 键 词：阿西美辛 双氯芬酸钠 成本效用 强直性脊柱炎 

分 类 号：R956[医药卫生—药学]